IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12071477 B1

PDFFull Text
Date of Patent:
Aug. 27, 2024

Filed:

Sep. 17, 2018

Anti-folate receptor alpha antibody conjugated with hemiasterlins

Applicant:

Sutro Biopharma, Inc., South San Francisco, CA (US);

Inventors:

Ryan Stafford, Emeryville, CA (US);

Alice Yam, Tiburon, CA (US);

Xiaofan Li, Fremont, CA (US);

Gang Yin, South San Francisco, CA (US);

Toni Kline, San Francisco, CA (US);

Cristina Abrahams, Burlingame, CA (US);

Venita De Almeida, San Carlos, CA (US);

Assignee:

SUTRO BIOPHARMA, INC., South San Francisco, CA (US);

Attorney:

Squire Patton Boggs (US) LLP

Primary Examiner:

Zachary C Howard

Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 9/19 (2006.01); A61K 38/06 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 31/395 (2006.01); A61K 31/537 (2006.01); A61K 38/08 (2019.01); A61K 38/12 (2006.01); A61K 47/64 (2017.01); C07D 487/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 9/19 (2013.01); A61K 38/06 (2013.01); A61K 39/3955 (2013.01); A61K 47/6811 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); A61K 31/537 (2013.01); A61K 31/5545 (2017.08); A61K 38/08 (2013.01); A61K 38/12 (2013.01); A61K 47/6425 (2017.08); A61K 47/6803 (2017.08); A61K 47/6877 (2017.08); C07D 487/00 (2013.01); C07K 2317/60 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. The variable light chains are those of trastuzumab. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods. The antibody conjugates comprise a non-natural amino acid at a site selected from the group consisting of HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, according to the Kabat, Chothia, or EU numbering scheme.

Find Patent Forward Citations

Loading…